Get the Stockscreener App
2.72
4.53%
-0.15
After Hours:
2.72
Lexeo Therapeutics Inc stock is traded at $2.72, with a volume of 370.96K.
It is down -4.53% in the last 24 hours and down -30.28% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$2.87
Open:
$2.87
24h Volume:
370.96K
Relative Volume:
0.39
Market Cap:
$90.30M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-0.9603
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
-2.84%
1M Performance:
-30.28%
6M Performance:
-66.71%
1Y Performance:
-82.93%
1-Day Range:
$2.67
$2.889
1-Week Range:
$2.5109
$3.08
52-Week Range:
$1.45
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
2.72 | 102.23M | 0 | -86.60M | -67.37M | -2.8324 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
BNP Paribas Financial Markets Buys 28,986 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo raises $80 million to shore up gene therapy work after layoffs - The Pharma Letter
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook - Investing.com Australia
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook By Investing.com - Investing.com India
Lexeo Therapeutics raises $80M in private placement (LXEO) - Seeking Alpha
Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares - Nasdaq
Lexeo Therapeutics Announces $80 Million Equity Financing - marketscreener.com
Lexeo prices 20.8M shares at $2.8825 in private placement - TipRanks
Lexeo Therapeutics Announces $80M Private Placement Agreement - TipRanks
Lexeo Therapeutics (LXEO) Secures $80M from Private Placement | LXEO Stock News - GuruFocus
Lexeo Therapeutics secures $80 million in private placement By Investing.com - Investing.com India
Lexeo Therapeutics secures $80 million in private placement - Investing.com
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of ... - Bluefield Daily Telegraph
Major Investors Back Lexeo Therapeutics with $80M for Breakthrough Genetic Heart Disease Programs - Stock Titan
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Price T Rowe Associates Inc. MD Acquires New Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Q1 Earnings Forecast for LXEO Issued By HC Wainwright - Defense World
FY2025 Earnings Forecast for LXEO Issued By Chardan Capital - Defense World
HC Wainwright Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $15.00 - Defense World
Lexeo stock price target cut to $15 by H.C. Wainwright - Investing.com South Africa
Lexeo Therapeutics price target lowered to $15 from $23 at H.C. Wainwright - TipRanks
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating - TipRanks
#ASGCT25: In three patients, Rocket’s second heart gene therapy shows promise - Endpoints News
Lexeo Therapeutics (LXEO) Analyst Rating Update and Price Target Adjustment | LXEO Stock News - GuruFocus
Lexeo Therapeutics (LXEO) Price Target Cut to $15 by H.C. Wainwr - GuruFocus
Leerink Partnrs Has Bearish Forecast for LXEO Q2 Earnings - Defense World
Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics: Strategic Focus and Promising Pipeline Drive Buy Rating - TipRanks
Lexeo Therapeutics (LXEO) Sees Price Target Adjustment by Charda - GuruFocus
Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
Lexeo Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Lexeo Therapeutics price target lowered to $20 from $22 at Chardan - TipRanks
Lexeo Trims 15% of Workforce, Shifts Focus to Lead Cardiac Programs - BioSpace
Lexeo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies - Fierce Biotech
Lexeo (LXEO) Projects Strong Financial Position and Clinical Adv - GuruFocus
Lexeo (LXEO) Projects Strong Financial Position and Clinical Advancements | LXEO Stock News - GuruFocus
Lexeo Therapeutics, Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights - The Manila Times
Lexeo Therapeutics Reports Positive Interim Data for LX2006 in Friedreich Ataxia Cardiomyopathy and Announces Upcoming Registrational Study Plans - Nasdaq
Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView
Lexeo Therapeutics reports Q1 EPS (99c), consensus (77c) - TipRanks
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Position Boosted by Barclays PLC - Defense World
Ratio Examination: Lexeo Therapeutics Inc (LXEO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Lexeo Therapeutics Inc (NASDAQ: LXEO) Still Pointing Downwards - Stocksregister
Lexeo Therapeutics Inc expected to post a loss of 78 cents a shareEarnings Preview - TradingView
17,794 Shares in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Bought by Marshall Wace LLP - Defense World
JPMorgan Chase & Co. Acquires 3,093 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (NASDAQ:LXEO) - Seeking Alpha
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
May 16 '25 |
Sale |
2.77 |
585 |
1,623 |
67,681 |
| Robertson Jenny | Chief Legal Officer |
May 16 '25 |
Sale |
2.77 |
521 |
1,445 |
63,098 |
| See Tai Sandi | Chief Development Officer |
May 16 '25 |
Sale |
2.77 |
367 |
1,018 |
59,242 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):